|
丁志華(2018)。矽晶・電子：矽說台灣–台灣半導體產業發展與全球地位。科學 發展，(541)，21-29。
王仁傑(2018)。台灣半導體科技的幕後推手與展望。科學發展，(541)。
汪嘉林(2011)。我國生技製藥產業創新演化的回顧與前瞻。科學發展月刊，(457)， 146-150。
余明隆(2017)。臺灣C型肝炎之治療現況。台灣醫學，21(6)，589 - 594。
林垂宙。國家創新機制對經濟發展的影響。工業技術與資訊月刊。
范佐勳(2001)。臺灣藥學史。台北市：財團法人鄭氏藥學文教基金會。
陳琮淵&王振寰(2009)。台灣的生技製藥產業：發展、創新與限制。台灣社會學刊，(43)，159-208。
湯明哲(2004)。IBM走出PC陰霾。天下雜誌，(313)，46-48。
曾倫崇、張益萌、蔣承哲、陳寬裕、邱文仁、郭純學(2002)。我國製藥業發展現況與策略之研究。遠東學報，(20)。
鄧哲明(2013)。新藥的研發流程概論。科學月刊，(44)。
劉軒彤(2021)。生技台積電！CDMO需求爆發「這些台廠」搶攻千億美元商機。財訊，(646)。
羅登義(2016)。國內醫藥業之營運模式及財報特性介紹。貨幣觀測與信用評等。
譚偉晟&黃浩珉(2022)。生技股100大 新藥股憑什麼夯？。今周刊，(1333)，50- 59。
譚雅芸(2016)。歐美日台早期臨床試驗計畫審查流程比較。當代醫藥法規月刊，(69)。
龔招健(2018)。工業技術與資訊月刊，(319)。
2021年台康生技永續報告書ESG Report。
台康生技股份有限公司民國一一○年度年報。
永昕生物醫藥股份有限公司民國一一○年度年報。
保瑞藥業股份有限公司民國一一○年度年報。
保瑞藥業股份有限公司2022年度營運成果報告。
聯合報(2016)。撥開迷霧看生技：生技，原來要這樣看。台北市：聯合報-健康事 業部。
經濟部工業局生技醫藥產業發展推動小組(民111)。2022生技產業白皮書。
經濟部工業局生技醫藥產業發展推動小組(民109)。2020生技產業白皮書。
二、英文部分
Ahmad Dar, R. (2021). Roles of Human Resource in Pharmaceutical Sector. IJCRT, 9(3).
Aigbavboa, S. & Mbohwa, C. (2020). The Murky Waters of Outsourcing: Critical Risks Factors of Outsourcing Pharmaceutical Outbound Value Chains. Procedia Manufacturing, 43, 328–335.
Alvarez, S. & Busenitz, L. (2001). The Entrepreneurship of Resource-based Theory. Journal of Management, 6, 755–775.
Arqawi, S. M., Al hila, A. A., Abu Naser, S. S. & Al Shobaki, M. J. (2019). Strategic Orientation and Its Relation to the Development of the Pharmaceutical Industry for Companies Operating in the Field of Medicine in Palestine. International Journal of Academic Management Science Research, 3, 61-70.
Babapour, J., Gholipourb, A., & Mehralian, G. (2018). Human Resource Management Challenges to Develop Pharmaceutical Industry: Evidence from Developing Countries. Iranian Journal of Pharmaceutical Research : IJPR, 17, 224–238.
Boulaksil, Y., & Fransoo, J. C. (2008). Strategic and Operational Outsourcing: Decisions in the Pharmaceutical Industry. Technische Universiteit Eindhoven, BETA Working Paper Series; Vol. 242.
Boulaksil, Y., & Fransoo, J. C. (2010). Implications of Outsourcing on Operations Planning : Findings from the Pharmaceutical Industry. International Journal of Operations and Production Management, 30(10), 1059-1079.
Bryce, D. J. & Useem, M. (1998). The Impact of Corporate Outsourcing on Company Value. European Management Journal, 16(6), 635-643.
Chambers, S. M., Fasano, C. A, Papapetrou, E. P., Tomishima, M., Sadelain, M. & Studer, L. (2009). Highly Efficient Neural Conversion of Human ES and iPS Cells by Dual Inhibition of SMAD Signaling. Nat Biotechnol, 27(3).
Chase, R. B., Kumar, K. R. & Youngdahl, W. E.(1992). Service-based Manufacturing:
the Service Factory, Production and Operations Management, 1(2).
Conner, K. (1991). A Historical Comparison of Resource-Based Theory and Five Schools of Thought within Industrial Organization Economics: Do We Have a New Theory of the Firm? Journal of Management, 17, 121-154.
Collis, D. J. & Montgomery, C. A. (1997). Corporate Strategy: Resources and the Scope of the Firm. Chicago:Irwin.
Cockburn, I. M. & Henderson, R. M. (2001). Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research. Journal of Health Economics, 20(6), 1033–1057.
Deavers, K.L. (1997). Outsourcing: A Corporate Competitiveness Strategy, not a Search for Low Wages. Journal of Labor Research, 18, 503–519.
Diao, Q. H., Fan, M. J., Fu, G.B., Li, Y. J. & Wang, H. A. (2008). An Overview of Biotechnology and Bio-industry in Switzerland. China Biotechnology, 28(8): 4-7.
Drozdoff, V., & Fairbairn, D. (2015). Licensing Biotech Intellectual Property in University-industry Partnerships. Cold Spring Harbor Perspectives in Medicine, 5(3).
Ehrismann D. & Patel D. (2015). University – Industry Collaborations: Models, Drivers and Cultures. Swiss Med Wkly.
Enyinda, C., Briggs, C., & Bachkar, K. (2009). Managing Risk in Pharmaceutical Global Supply Chain Outsourcing: Applying Analytic Hierarchy Process Model. ASBBS Annual Conference: LasVegas, 16(1).
Ezell, S. (2019). The Bayh-Dole Act’s Vital Importance to the U.S. Life-Sciences Innovation System. ITIF’s Center for Life Sciences Innovation.
Gambardella, A. (1995). Science and Innovation: The US Pharmaceutical Industry During the 1980. Cambridge University Press.
Gassmann, O. & Keupp, M. M. (2007). The Competitive Advantage of Early and Rapidly Internationalising SMEs in the Biotechnology Industry: A Knowledge-based View. Journal of World Business, 42(3), 350-366.
Garza‐Reyes, J.A., Lal, J.S., & Rocha-Lona, L. (2012). Exploring the Advantages and Disadvantages of Outsourcing the Development of New Products in the Indian Pharmaceutical Industry.
Gebhardt, C. (2017). Island of Bliss? University Technology Commercialization Practices in the Swiss Innovation System. University Technology Transfer, 169-198.
Grant, R. M. (1999). The Resource-Based Theory of Competitive Advantage: Implications for Strategy Formulation. California Management Review, 33(3), 3-23.
Gurgula O. (2020). Strategic Patenting by Pharmaceutical Companies - Should Competition Law Intervene?. International Review of Industrial Property and Copyright Law, 51(9), 1062–1085.
Goodman, J. (2000). Medicine in the Twentieth Century. Taylor & Francis.
Handley, S. M. & Benton, W., Jr. (2012). Mediated Power and Outsourcing Relationships. Journal of Operations Management, 30, 253-267.
Harada, Y., Wang, H., Kodama, K., & Sengoku, S. (2021). Drug Discovery Firms and Business Alliances for Sustainable Innovation. Sustainability, 13(7), 3599.
Harrison, Hitt, M., Hoskisson, R. E., & Ireland, D. (2001). Resource Complementarity in Business Combinations: Extending the Logic to Organizational Alliances. Journal of Management, 6.
Hather, G. J., Haynes, W., Higdon, R., Kolker, N., & Stewart, E. A. et al. (2010). The United States of America and Scientific Research. PLOS ONE, 5(8).
Herrmann, A. M. (2008). Contrasting the Resource-based View and Competitiveness Theories: How Pharmaceutical Firms Choose to Compete in Germany, Italy and the UK. Strategic Organization, 6(4), 343–374.
Herrmann, A. M. (2008). Contrasting the Resource-Based View and Competitiveness Theories: How Pharmaceutical Firms Choose to Compete in Germany, Italy and the UK. Strategic Organization, 6(4), 343–374.
Hooft van Huijsduijnen, R., Wells, T., Tanner, M., & Wittlin, S. (2019). Two Successful Decades of Swiss Collaborations to Develop New Anti-Malarials. Malaria journal, 18(1), 1-7.
Holdford, D. A. (2018). Resource-Based Theory of Competitive Advantage - a Framework for Pharmacy Practice Innovation Research. Pharmacy Practice, 16(3):1351.
Hotz-Hart, B. (2012). Innovation Switzerland: A Particular Kind of Excellence. Innovation Policy and Governance in High-Tech Industries. Springer, Berlin, Heidelberg.
Hoskisson, R. E., Eden, L., Lau, C-M. & Wright, M. (2000). Strategies in Emerging Economies. Academy of Management Journal, 43 (3), 249–267.
Hole, G., Hole, A. S. & McFalone-Shaw, I. (2021). Digitalization in pharmaceutical industry: What to focus on under the digital implementation process?. International Journal of Pharmaceutics: X, 3.
Huggett, B. (2013). University Biotech Patenting. Nature Biotechnology, 31, 589.
Huggett, B. & Paisner, K. (2021). Biotech Patenting 2020. Nature Biotechnology, 39,
1176-1177.
Interpharma. (2021). Importance of the Pharmaceutical Industry for Switzerland. Interpharma, Switzerland, Basel.
Jackson, J. K., MacDonald, K. L. & Fildes, N. J. (1990). Absence of HIV Infection in Blood Donors with Indeterminate Western Blot Tests for Antibody to HIV-1. The New England Journal of Medicine.
Jensen, M. (1993). The Modern Industrial Revolution, Exit, and the Failure of Internal Control Systems. Journal of Finance, 48, 831–880.
Jones, J., & Minor, M. (2010). New, Strategic Outsourcing Models to Meet Changing Clinical Development Needs. Perspectives in clinical research, 1(2), 76–79.
Kesselheim, A. S., & Avorn, J. (2005). University-based Science and Biotechnology Products: Defining the Boundaries of Intellectual Property. JAMA, 293(7), 850-854.
Keyhani, S., Wang, S., Hebert, P., Carpenter, D., & Anderson, G. (2010). US Pharmaceutical Innovation in an International Context. American Journal of Public Health 100.
Kim, K., Hyun, B. H. & Chung S. (2007). U.S. National Innovation System for Biotechnology: From the Korean Perspectives. PICMET Proceedings, 5-9.
Kor, Y. Y. & Mahoney, J. T. (2004). Edith Penrose’s (1959) Contributions to the Resource-based View of Strategic Management. Journal of Management Studies, 41:1.
Kurata, H., Ishino, T., Ohshima, Y. & Yohda, M. (2022). CDMOs Play a Critical Role in the Biopharmaceutical Ecosystem. Front Bioeng Biotechnol, 10.
Kremic, T., Icmeli Tukel, O. & Rom, W.O. (2006). Outsourcing Decision Support: A Survey of Benefits, Risks, and Decision Factors. Supply Chain Management, 11(6), 467–482.
Lawton-Smith, H., Bagchi-Sen, S. & Edmunds, L. (2016). Innovation Capacity in the Healthcare Sector and Historical Anchors: Examples from the UK, Switzerland and the US. The Journal of Technology Transfer, 41 (6), 1420-1439.
Lakdawalla, D. N. (2018). Economics of the Pharmaceutical Industry. Journal of Economic Literature, 56(2), 397-449.
Laínez, J. M., Schaefer, E. & Reklaitis, G. V. (2012). Challenges and Opportunities in Enterprise-wide Optimization in the Pharmaceutical Industry. Computers & Chemical Engineering, 47, 19-28.
Liu, M. (2021). Taiwan and the Foundry Model. Nat Electron, 4, 318–320.
Liu, S. J. (1998). Industrial Development and Structural Adaptation in Taiwan. IEEE Transactions on Engineering Management, 45, 4.
Mathews, J. A. (1997) A Silicon Valley of the East: Creating Taiwan’s Semiconductor Industry. California Management Review, 39, 4.
Mathews, J.A. (2002). The Origins and Dynamics of Taiwan’s R&D Consortia. Research Policy, 31(4), 633–651.
Mathews, J.A. (2002). Competitive Advantages of the Latecomer Firm: a Resource-based Account of Industrial Catch-up Strategies. Asia Pacific Journal of Management, 19, 467–488.
Mathews, J. A. & Cho, D. S. (2000). Tiger Technology: The creation of Semiconductor Industry in East Asia. Cambridge University Press.
Mahoney, J.T. and Pandian, J.R. (1992). The Resource-Based View within the Conversation of Strategic Management. Strategic Management Journal, 13, 363-380.
Marxt, C. & Brunner, C. (2013). Analyzing and Improving the National Innovation System of Highly Developed Countries — The Case of Switzerland. Technological Forecasting and Social Change, 80(6), 1035-1049.
McWilliams, A., & Siegel, D. (2001). Corporate Social Responsibility: A Theory of the Frm Perspective. Academy of Management Review, 26 (1), 117–127.
Metcalfe, J. S. (1995). Technology Systems and Technology Policy in an Evolutionary Framework. Cambridge Journal of Economics, 19, 25-46.
Montgomery, C. A. (1995). Resource-Based and Evolutionary Theories of the Firm,
Towards a Synthesis.
Nelson, R. R. (1991). Why Do Firms Differ, and How Does it Matter?. Strategic Management Journal, 12, 61-74.
Penrose, E.T. (1959). The Theory of the Growth of the Firm. John Wiley & Sons, New
York.
Prahalad, C.K. & Hamel, G. (1990). The Core Competence of the Corporation. Harvard Business Review, 79-91.
Proksch, D., Busch-Casler, J., Haberstroh, M. M. & Pinkwart, A. (2019). National Health Innovation Systems: Clustering the OECD Countries by Innovative Output in Healthcare Using a Multi Indicator Approach. Research Policy, 48, 169-179.
Rangone, A. A. (1999). Resource-Based Approach to Strategy Analysis in Small-Medium Sized Enterprises. Small Business Economics, 12, 233–248
Rothaermel, F. T., Hitt, M. A. & Jobe, L. A. (2006). Balancing Vertical Integration and Strategic Outsourcing: Effects on Product Portfolio, Product Success, and Firm Performance. Strategic Management Journal, 27, 1033-1056.
Rumelt, R.P. (1984). Towards a Strategic Theory of the Firm. Competitive Strategic Management, 26, 556-570.
Saha, E., Rathore, P., Parida, R. & Rana, N. P. (2022). The Interplay of Emerging Technologies in Pharmaceutical Supply Chain Performance: An Empirical Investigation for the Rise of Pharma 4.0, Technological Forecasting and Social Change, 181.
Sinha, G. (2004). Outsourcing Drug Work. Pharmaceuticals Ship R&D and Clinical Trials to India. Scientific American, 291.
Subramaniam, S. & Dugar, S. (2012). Outsourcing Drug Discovery to India and China: From Surviving Thriving. Drug Discovery Today, 17.
Teece, D. J., Pisano, G., & Shuen, A. (1997). Dynamic Capabilities and Strategic Management. Strategic Management Journal, 18(7), 509–533.
Tollman, P., Morieux, Y., Murphy, J. K., & Schulze, U. (2011). Identifying R&D Outliers. Nature Reviews Drug Discovery, 10(9), 653–654.
Villemeur, E.B., Scannell, J.W., & Versaevel, B. (2022). Biopharmaceutical R&D Outsourcing: Short-Term Gain for Long-Term Pain?. Drug Discovery Today, 27(11).
Vock, P. (2003). University Technology Transfer in Switzerland Organisation, Legal Framework, Policy and Performance. S ytyrÁRhtpyhpÁ ty Á5 typ, 189.
Wade, R. H. (2005). Bringing the State Back In: Lessons from East Asia’s
Development Experience.
Wernerfelt, B. (1984). A Resource-based View of the Firm. Strategic Management
Journal, 5, 171-180.
Webber, D. J. (1995). The Emerging Federalism of U.S. Biotechnology Policy. Politics and the Life Sciences, 14(1), 65-72.
Winter, S. G. (1995). Four Rs of Profitability: Rents, Resources, Routines and Replication. International Institute for Applied Systems Analysis.
Wright, M., Hoskisson, R., & Busenitz, L. (2001). Firm Rebirth Buyouts as Facilitators of Strategic Growth and Entrepreneurship. Academy of Management Executive, 15 (1), 111–125.
Wright, P., Dunford, B., & Snell, S. (2001). Human Resources and the Resource-based View of the Firm. Journal of Management, 6, 701–721.
Yeoh, P.-L., & Roth, K. (1999). An Empirical Analysis of Sustained Advantage in the U.S. Pharmaceutical Industry: Impact of Firm Resources and Capabilities. Strategic Management Journal, 20(7), 637–653.
(2022). EMA Competency Framework. European Medicines Agency.
2022 Global CDMO Study of Pharmaceutical Operations. PwC.
三、網頁資料
Max(民111年12月27日)。台灣製藥產業分析｜製藥產業鏈介紹？製藥概念股有哪些？製藥產業可以投資嗎？。Max金融生活頻道。民112年2月9日，取自：https://maxfinanciallife.com/%E7%94%A2%E6%A5%AD%E9%8F%88-%E6%A6%82%E5%BF%B5%E8%82%A1-%E8%A3%BD%E8%97%A5/
毛遠誠(民93)。台灣電子業的發展。民111年12月15日，取自：https://blog.xuite.net/freedomgood/twblog/113482656#
余弦妙(民111年9月14日)。沈榮津：台灣半導體產值突破4兆 代工、封測世界第一。經濟日報。民111年12月15日，取自：https://money.udn.com/money/story/5612/6610879
花穗珍(民110年6月12日)。40年前保生疫苗慘敗 今日莫要重蹈覆轍。資訊網路通訊科技。民112年5月12日，取自：https://www.lawtw.com/archives/473812
吳元熙(民110年9月30日)。【圖解】CDMO是什麼？生技界「台積電模式」，為何讓郭董大砸50億元投資？。數位時代。民111年12月7日，取自：https://www.bnext.com.tw/article/65295/cdmo
許家禎(民110年11月8日)。台灣生技業沒那麼弱！創新不輸日韓。今日新聞。民111年12月12日，取自：https://tw.news.yahoo.com/%E5%8F%B0%E7%81%A3%E7%94%9F%E6%8A%80%E6%A5%AD%E6%B2%92%E9%82%A3%E9%BA%BC%E5%BC%B1-%E5%89%B5%E6%96%B0%E4%B8%8D%E8%BC%B8%E6%97%A5%E9%9F%93-020000935.html
趙建雄(民98年9月24日)。勞力密集代工產業。文化部台灣大百科全書。民111年12月15日，取自：https://nrch.culture.tw/twpedia.aspx?id=4106
蔣濬浩(民111年7月30日)。生技新契機？永昕、台康領銜CDMO三大機會。遠見。民111年12月7日，取自：https://www.gvm.com.tw/article/92558
謝柏宏(民110年12月26日)。生技業委託生產商機爆發。經濟日報。民111年12月7日，取自：https://udn.com/news/story/7241/5988166
蘇思云&韓婷婷(民111年9月18日)。新矽盾崛起 盛保熙：台灣有條件成為亞洲CDMO中心【專訪】。中央社。民111年12月7日，取自：https://www.cna.com.tw/news/afe/202209180037.aspx
魏傳虔(民110)。台灣產業總覽。2021資訊硬體產業年鑑，11-14。民111年12月15日，取自：https://books.google.com.tw/books?id=i71LEAAAQBAJ&pg=PA6&source=gbs_selected_pages&cad=2#v=onepage&q&f=false
新聞傳播處(民105年11月18日)。重要政策 推動台灣生技醫療產業發展—打造台灣成為亞太生醫研發產業重鎮【公告】。台北市：行政院。民111年12月7日，取自：https://www.ey.gov.tw/Page/5A8A0CB5B41DA11E/db872f57-80cb-4122-bfba-ef401369293d
產經新聞網媒體中心(民109年11月9日)。生技製藥產業裡的化學工程師 - LEAP 學人劉原安。產經新聞網。民111年12月15日，取自：https://www.1111.com.tw/news/jobns/134576
資策會(民111年6月15日)。2022全球半導體市場規模6135億美元 成長10.4% 臺灣半導體成長率17.5% 產值達4.36兆新台幣。MIC產業情報研究所。民111年12月15日，取自：https://mic.iii.org.tw/news.aspx?id=624&List=10
國家生技醫療產業策進會(民111年10月17日)。全球Top10製藥CDMO公司營運綜覽。社團法人國家生技醫療產業策進會。民111年12月15日，取自：https://ibmi.taiwan-healthcare.org/zh/bio_highlights_detail.php?REFDOCID=0rjonvnph8eitmo4
製藥產業鏈簡介。產業價值鏈資訊平台。民111年2月10日，取自：https://ic.tpex.org.tw/introduce.php?ic=C100
台杉投資(民110年9月23日)。基因線上：mRNA、細胞療法趨勢來襲！台灣新藥研發該思考的黃金策略。台杉投資。民112年4月19日，取自：https://geneonline.news/taiwan-pharma-strategy-interview/
生物技術開發中心(民112年2月24日)。【國內CDMO產業在美國國家生技及生物製造倡議之下的發展與契機】專家討論。生物技術開發中心DCB。民112年3月31日，取自：https://www.youtube.com/watch?v=UFAzBrhBCpQ&t=2938s
民視(民111年10月16日)。【決策者 Ep29 民視新聞】CDMO成趨勢生技搶卡位 9年6併打造"製藥業台積電" 保瑞藥業集團董事長盛保熙專訪。民視讚夯 Formosa TV Thumbs Up。民112年3月31日，取自：https://www.youtube.com/watch?v=7UxrIOiXuzE
非凡財經新聞(民110年9月23日)。郭台銘砸重金參股！專訪台康總經理劉理成：雙強聯手啟動4階段擴產。非凡財經新聞。民112年3月31日，取自：https://www.youtube.com/watch?v=egWVEQHQGgE
產業人力供需資訊網(民112年5月11日)。未來3年重點產業人才調查及推估 生技產業。產業人力供需資訊網。民112年5月12日，取自：https://theme.ndc.gov.tw/manpower/cp.aspx?n=D2A88BB69A871C91
行政院科技會報辦公室(民109年8月27日)。生醫產業創新推動方案成果。行政院科技會報辦公室。民112年5月12日，取自： https://www.ey.gov.tw/Page/448DE008087A1971/8c104e42-e4f9-40aa-a942-adc242935bb5
Ascendia Pharma. (2021, June 30). Solved: What Is a CDMO (and Why Do You Need One)?. Ascendia Pharma. Retrieved from https://ascendiapharma.com/newsroom/2021/06/30/pharmaceutical-cdmos
Blok, D. (2022, October 28). How did a Small Country like Switzerland Become a Pharma Giant?. Pharmaoffer.com. Retrieved from https://pharmaoffer.com/blog/how-did-a-small-country-like-switzerland-become-a-pharma-giant/
Encyclopedia. com. (2018, June 8). Pharmaceutical Industry. Encyclopedia.com. Retrieved from https://www.encyclopedia.com/medicine/drugs/pharmacology/pharmaceutical-industry#:~:text=Pharmaceutical%20firms%20are%20engaged%20in,for%20both%20humans%20and%20animals
Heiber, I. (2022). How CDMOs are Leading Innovation for Pharmaceutical Partners. EY-Parthenon. Retrieved from https://www.ey.com/en_qa/strategy/how-cdmo-companies-are-leading-innovation-for-pharmaceutical-partners
Joshi, M., Abidi, S. & Chauhan, A. (2021, June 8). Contract Pharma-The Neglected Sector. BW Businessworld. Retrieved from https://www.businessworld.in/article/Contract-Pharma-The-Neglected-Sector/08-06-2021-392301/
Kramer, K. (2022, September 29). An evolution in pharma outsourcing.
Chemistry World. Retrieved from
https://www.chemistryworld.com/news/an-evolution-in-pharma- outsourcing/4016264.article
Millar, A. (2018, June 13). A Formula for Success: Inside Swiss Pharma. Pharmaceutical Technology. Retrieved from https://www.pharmaceutical-technology.com/features/formula-success-inside-swiss-pharma/
Scorpius BioManufacturing. (2023, May 1). An Experienced CDMO Can Be a Differentiator in the Rapidly Growing Biologics Market. Scorpius BioManufacturing. Retrieved from https://www.biopharma-reporter.com/Headlines/Promotional-Features/An-Experienced-CDMO-Can-Be-a-Differentiator-in-the-Rapidly-Growing-Biologics-Market
U.S. Food & Drug Administration. (2018, January 4). The Drug Development Process. U.S. Food & Drug Administration. Retrieved from
https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process
U.S. Department of Defense. (2022, September 14). New Biotechnology Executive Order Will Advance DoD Biotechnology Initiatives for America’s Economic and National Security. The Under Secretary of Defense for Research and Engineering USD(R&E). Retrieved from https://www.defense.gov/News/Releases/Release/Article/3157504/new-biotechnology-executive-order-will-advance-dod-biotechnology-initiatives-fo/
|